Wu J, Wang J, Su Q, et al. Onco Targets Ther. 2018;11:2685–2698.
The authors have advised the incorrect images were inadvertently selected for Figure 2A, on page 2690, due to the dark background and relatively low resolution of photos captured for the wound healing assay. For Figure 3A on page 2691, all Transwell images were captured and saved in one folder labelled by experimental date. Two overlapping images from different visual fields were captured from one well but labelled incorrectly and inadvertently selected for Figure 3A.
Figure 2.
APS enhanced the inhibition of cell migration suppressed by apatinib.
Notes: Wound healing analysis of AS PC-1 (A and B) and PANC -1 (C and D) cell migration for 0 and 24 hours; cells were treated with control, 40 µM apatinib, 200 µg/mL APS, and 40 µM apatinib + 200 µg/mL APS. *P<0.05, ***P<0.001 versus control; ###P<0.001 versus apatinib. Original magnification ×40.
Abbreviation: APS, Astragalus polysaccharide.
Figure 3.
APS enhanced the inhibition of cell invasion suppressed by apatinib.
Notes: Transwell analysis of AS PC-1 (A and B) and PANC -1 (C and D) cell invasion for 24 hours; cells were treated with control, 40 µM apatinib, 200 µg/mL APS, and 40 µM apatinib + 200 µg/mL APS. Original magnification ×100. (E) MMP-9 protein expression treated with different groups after 24 hours were determined by Western blotting. β-Actin was used as the internal control. **P<0.01, ***P<0.001 versus control; #P<0.05 versus apatinib.
Abbreviations: AP, apatinib; APS, Astragalus polysaccharide; MMP-9, matrix metalloproteinases-9.
The correct Figures 2 and 3 are as follows.
The authors apologize for these errors and advise they do not affect the results of the paper.